Nxera Pharma Posts Strong Q1 2026 Momentum on Asia-Pacific Deals and Milestones

The latest announcement is out from Sosei Group ( (JP:4565) ).

Nxera Pharma reported strong operational momentum in the first quarter of 2026, highlighted by a licensing deal with Santhera to develop and commercialize vamorolone for Duchenne Muscular Dystrophy in key Asia-Pacific markets. The company also advanced insomnia drug daridorexant in South Korea and Taiwan, securing positive Phase 3 data, a marketing authorization filing with Korean regulators and marketing approval through its partner Holling Bio-Pharma in Taiwan.

In its partnered R&D portfolio, Nxera booked multiple milestones from collaborations with Centessa, Eli Lilly and Neurocrine Biosciences tied to progress of orexin receptor agonists and muscarinic agonists in schizophrenia, bipolar mania, Alzheimer’s disease and metabolic indications. The planned acquisition of Centessa by Eli Lilly validates the value of Nxera’s orexin platform and preserves its future milestone and royalty rights, reinforcing the company’s financial position and supporting its strategy to drive sustained growth across both commercial and discovery businesses.

The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma, listed on the Tokyo Stock Exchange, operates as a specialty pharmaceutical and drug discovery company with commercial operations focused on Japan and the broader Asia-Pacific region. The group develops and commercializes therapies in areas of high unmet medical need, while its UK-based discovery arm leverages its proprietary GPCR and orexin-focused platform to build both partnered and proprietary pipelines with major global pharma partners.

Average Trading Volume: 903,728

Technical Sentiment Signal: Hold

Current Market Cap: Yen87.87B

See more data about 4565 stock on TipRanks’ Stock Analysis page.